Celiac Panel: What This Test Actually Measures

What the Celiac Panel Is Actually Testing

The celiac panel does not measure a single biomarker. It measures a coordinated set of autoantibodies that arise when genetically susceptible individuals ingest gluten, the protein fraction found in wheat, barley, and rye. When gluten-derived peptides cross a damaged intestinal barrier, the enzyme tissue transglutaminase 2 (tTG2) deamidates them, creating neo-epitopes that the immune system attacks. The antibodies generated against tTG2 and these modified peptides are exactly what the panel detects.

The ACG (American College of Gastroenterology) 2023 clinical guideline states: "Serologic testing with IgA anti-tissue transglutaminase (tTG) antibody is the recommended initial test for the diagnosis of celiac disease in individuals on a gluten-containing diet." [1] A positive result identifies patients likely enough to have celiac disease that tissue sampling is the next appropriate step.

The Four Core Tests in a Standard Panel

Most clinical laboratories and major reference labs bundle the following four assays under the "celiac panel" order code:

1. tTG-IgA (tissue transglutaminase IgA): the anchor test. Sensitivity reaches 91-99% and specificity approximately 95% in large validation cohorts. [2]
2. Total serum IgA: a quality-control test, not a celiac marker per se. Selective IgA deficiency falsely normalizes tTG-IgA results, so total IgA must be checked simultaneously. [3]
3. DGP-IgA and DGP-IgG (deamidated gliadin peptide antibodies): second-generation assays that replaced older native gliadin tests. DGP-IgG is the preferred marker when total IgA is <7 mg/dL (IgA-deficient). [2]
4. EMA-IgA (endomysial antibody IgA): highly specific (>98%) but operator-dependent and less commonly used for initial screening. [4] Some panels include it; others reserve it for equivocal tTG-IgA results.

Why Total IgA Cannot Be Skipped

Selective IgA deficiency affects roughly 1 in 400-500 people in the general population, a rate 10 to 15 times higher in patients with celiac disease than in healthy controls. [3] A patient with IgA deficiency and untreated celiac disease will produce a falsely low or undetectable tTG-IgA result. The ACG 2023 guideline explicitly recommends: "In patients with IgA deficiency, IgG-based serology (IgG tTG or IgG DGP) should be used." [1] Ordering a celiac panel without the total IgA anchor leaves a diagnostic gap that can delay a correct diagnosis by years.

Reference Ranges and How to Read Your Numbers

Reference ranges vary by assay platform and laboratory. No universal single cut-off applies to all instruments. The two most common conventions are listed here.

Quantitative tTG-IgA Cut-Offs

| Result tier | Common cut-off (ELISA units) | Clinical interpretation | |---|---|---| | Negative | <4 U/mL (some labs: <20 U/mL) | Celiac disease unlikely if on a gluten-containing diet | | Weakly positive | 4-10 U/mL or 20-30 U/mL | Borderline; repeat testing or additional antibody workup recommended | | Positive | >10 U/mL or >30 U/mL | Significant autoimmune activity; biopsy indicated | | Strongly positive | >10x upper limit of normal (ULN) | In children, may meet no-biopsy diagnostic criteria per ESPGHAN 2020 [5] |

The ESPGHAN 2020 revised guidelines allow pediatric gastroenterologists to diagnose celiac disease without biopsy when tTG-IgA exceeds 10x ULN, EMA-IgA is also positive on a separate blood draw, and the child carries HLA-DQ2 or HLA-DQ8. [5] For adults, biopsy remains the standard confirmation step regardless of antibody titer.

DGP-IgA and DGP-IgG Ranges

DGP antibody units are reported as a ratio or in U/mL depending on the platform. Most labs flag results >20 U/mL as positive. DGP-IgG is particularly useful in children under 2 years, where tTG-IgA sensitivity may be lower, and in IgA-deficient patients of any age. [2]

EMA-IgA: Positive or Negative

EMA-IgA is reported qualitatively (positive or negative with a titer such as 1:5 or 1:10) because it is read under immunofluorescence. Any detectable EMA-IgA titer in a symptomatic patient carries high specificity and strengthens the case for biopsy. [4]

What a High Celiac Panel Result Means

A high result, meaning a tTG-IgA above the laboratory's upper reference limit, signals that the immune system is generating antibodies against intestinal tissue. This does not automatically confirm celiac disease. It means the probability is high enough that biopsy is warranted.

Conditions That Can Raise tTG-IgA Without Celiac Disease

Mildly elevated tTG-IgA (1-3x ULN) can occur in:

• Type 1 diabetes mellitus (autoimmune overlap; prevalence of celiac disease in T1DM is 5-10%) [6]
• Autoimmune thyroid disease, including Hashimoto thyroiditis and Graves disease
• Inflammatory bowel disease, particularly Crohn disease affecting the small bowel
• Microscopic colitis and other autoimmune enteropathies
• Liver disease, including autoimmune hepatitis and primary biliary cholangitis [4]

A tTG-IgA more than 3-5x ULN has much higher positive predictive value for true celiac disease. Results above 10x ULN have a positive predictive value exceeding 95% for Marsh 2-3 histology on biopsy. [5]

The Biopsy Step

The ACG 2023 guideline states biopsy of the proximal small bowel remains the diagnostic gold standard for adults. Pathology is graded on the modified Marsh-Oberhuber scale: Marsh 1 (increased intraepithelial lymphocytes), Marsh 2 (crypt hyperplasia added), Marsh 3a-3c (partial to total villous atrophy). A positive celiac panel combined with Marsh 3 histology confirms the diagnosis and triggers a gluten-free diet as treatment. [1]

What a Low or Negative Celiac Panel Result Means

A negative tTG-IgA in a patient actively consuming gluten makes celiac disease unlikely. "Unlikely" is not "impossible." False negatives occur in two main scenarios.

IgA Deficiency as a False-Negative Cause

As noted above, a patient with total IgA <7 mg/dL produces no detectable IgA-class antibodies. If total IgA was not ordered simultaneously, the negative tTG-IgA result is uninterpretable. The solution: test DGP-IgG and tTG-IgG. [3]

Gluten Withdrawal Before Testing

Patients who have already started a gluten-free diet, even partially, will show declining antibody titers within weeks. The ACG 2023 guideline specifies that patients should consume at least 3 grams of gluten daily (roughly two slices of wheat bread) for a minimum of 6-8 weeks before testing. [1] Antibody levels fall below detectable thresholds in some patients within 3-6 months of strict gluten avoidance. [7]

A practical pre-test checklist for ordering clinicians:

1. Confirm the patient has consumed gluten daily for at least 6 weeks.
2. Order total serum IgA alongside tTG-IgA on the same requisition.
3. If total IgA <7 mg/dL, add DGP-IgG and tTG-IgG.
4. Document current diet and any prior GI evaluations in the chart.
5. If antibodies are negative but clinical suspicion remains high (weight loss, malabsorption, unexplained iron/B12 deficiency), consider HLA-DQ2/DQ8 genotyping. A negative HLA result has a negative predictive value >99% and effectively excludes celiac disease. [8]

Celiac Disease and Common Lab Overlaps

Clinicians ordering a celiac panel often do so because of secondary findings on a routine metabolic or CBC panel. Understanding why these overlaps exist prevents missed diagnoses.

Iron-Deficiency Anemia

Iron absorption occurs primarily in the duodenum and proximal jejunum, the exact regions where villous atrophy develops in celiac disease. A 2020 systematic review published in the American Journal of Gastroenterology found celiac disease in 3-15% of patients presenting with unexplained iron-deficiency anemia who had no obvious gastrointestinal blood loss. [9] Adding a celiac panel to the workup of unexplained iron deficiency is cost-effective and endorsed by the ACG.

Vitamin B12 and Folate Deficiency

Terminal ileal involvement or secondary small bowel bacterial overgrowth in untreated celiac disease can impair B12 and folate absorption. A patient presenting with macrocytic anemia, elevated homocysteine, or peripheral neuropathy of unclear origin should have celiac serologies checked. [9]

Autoimmune Thyroid Disease

The thyroid-celiac connection is well-documented. A meta-analysis of 16 studies found the prevalence of celiac disease in patients with autoimmune thyroid disease was approximately 3.3%, compared to 0.6-1% in controls. [10] The ACG 2023 guidelines specifically list autoimmune thyroid disease as a condition warranting celiac antibody screening even in the absence of GI symptoms. [1]

Practically, a patient on levothyroxine whose thyroid function is unexpectedly difficult to control despite adequate dosing should be evaluated for celiac disease, since malabsorption of levothyroxine in an inflamed small bowel is a documented mechanism. [10]

Type 1 Diabetes

The shared HLA-DQ2 and HLA-DQ8 haplotypes that predispose to celiac disease also predispose to type 1 diabetes. The American Diabetes Association's Standards of Care 2024 recommend screening for celiac disease at diagnosis of T1DM and repeating serology if symptoms develop or antibody-negative status needs reconfirmation. [6]

How Antibody Levels Change Over Time

The celiac panel is not only a diagnostic tool. It tracks treatment response on a gluten-free diet and can identify dietary non-adherence before symptoms return.

Expected Decline After Starting a Gluten-Free Diet

TTG-IgA levels typically fall 50% within 3-6 months of strict gluten avoidance and reach the normal reference range in 12-24 months in most patients. [7] A 2019 study in the United European Gastroenterology Journal (N=366) found that 80% of adult patients with celiac disease normalized their tTG-IgA within 24 months on a strict gluten-free diet. [7]

Persistently Elevated Antibodies After Diagnosis

If tTG-IgA remains elevated beyond 12-24 months despite reported adherence, consider:

• Inadvertent gluten cross-contamination in processed foods or shared cooking surfaces
• Oats sensitivity (a minority of celiac patients react to avenin in oats)
• Refractory celiac disease type 1 or type 2 (rare, requires specialist management)
• Alternative diagnosis such as non-celiac gluten sensitivity (NCGS), which does not produce elevated tTG-IgA

Repeat biopsy is indicated for persistently elevated serologies after 24 months of adherence. [1]

Monitoring Schedule

The ACG recommends serologic monitoring at 6 months after diagnosis, then annually once tTG-IgA is within the reference range. [1] There is no validated tTG-IgA target that definitively confirms mucosal healing; histologic normalization lags behind serologic normalization by months to years in adults. [4]

HLA Genotyping as a Companion Test

The celiac panel measures immune response. HLA-DQ2/DQ8 genotyping measures genetic susceptibility. These tests serve different clinical functions.

Approximately 95% of people with celiac disease carry HLA-DQ2 (subtype DQ2.5 most commonly) and most of the remaining 5% carry HLA-DQ8. [8] However, roughly 30-40% of the general population also carries these alleles without ever developing celiac disease. This means HLA testing has excellent negative predictive value but poor positive predictive value in isolation.

When to order HLA genotyping:

• Equivocal or borderline serology with high clinical suspicion
• Patient already on a strict gluten-free diet and cannot complete a gluten challenge
• First-degree relatives of confirmed celiac patients who want a one-time exclusionary test
• Evaluation for potential no-biopsy diagnosis pathway in children (requires DQ2/DQ8 positivity per ESPGHAN 2020) [5]

A negative HLA-DQ2 and HLA-DQ8 result makes celiac disease extremely unlikely (negative predictive value >99%) and can prevent unnecessary repeat testing or gluten challenges. [8]

Interpreting the Celiac Panel in Special Populations

Children Under Age 2

TTG-IgA may be less sensitive in very young children because the immune system has not yet fully matured. DGP-IgG performs comparably or better in this age group. [2] Any child with failure to thrive, chronic diarrhea, or unexplained iron deficiency in the first two years of life should be tested with both tTG-IgA and DGP-IgG.

Elderly Adults

Older adults with celiac disease may present with atypical features: osteoporosis, neurological symptoms, or dermatitis herpetiformis rather than classic GI complaints. Antibody titers may be lower in elderly patients with celiac disease than in younger cohorts, meaning a weakly positive result in this population still deserves full diagnostic evaluation. [4]

Patients With Established Autoimmune Conditions

Patients with type 1 diabetes, autoimmune thyroid disease, primary Sjogren syndrome, or Turner syndrome carry a 3-10 times higher lifetime risk for celiac disease compared to the general population. [6] Annual or biannual celiac panel monitoring is reasonable in symptomatic patients within these groups even after an initial negative result.

When to Repeat or Expand the Panel

A single negative celiac panel does not permanently exclude celiac disease in a high-risk or symptomatic individual. Repeat testing is appropriate when:

• Symptoms persist or worsen despite a negative initial result
• A new first-degree relative is diagnosed with celiac disease
• New onset of iron-deficiency anemia, unexplained B12 deficiency, or osteoporosis in the absence of other causes
• The initial panel was drawn after dietary gluten restriction had already begun
• The initial panel lacked total serum IgA

Expanding beyond the standard panel to include HLA-DQ2/DQ8 is reasonable after two negative serologic workups in a patient with strong clinical or family history. [8]